A United States-Based Real-World Study on Biomarker Testing and Rebiopsy Rates Among Patients With Non-Small Cell Lung Cancer Across Lines of Therapy
While tissue was most frequently used in 1L testing, rebiopsy was less frequent in 2L + . Racial and sex differences in rebiopsy/testing rates were observed. Standardization for 2L + biomarker testing is needed to optimize later-line treatment decisions for patients with a/mNSCLC.
Authors
- Sophia Ng (ORCID: https://orcid.org/0000-0001-7817-7744)
- Sue Beruti
- Mary Beth Beasley (ORCID: https://orcid.org/0000-0003-2340-1897)
- Rajesh Kamalakar
- Archana R. Simmons
- Charu Aggarwal (ORCID: https://orcid.org/0000-0002-3181-9460)
Institutions
- AbbVie (United States) (US)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1016/j.cllc.2025.11.017
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00